Ajouter aux favoris   Ajouter cette page à mon bookmark --- SOCIAL BOOKMARKING --- Digg Furl del.icio.us Netscape

Introduction
The global anxiety disorders market is set to decline from $4.5 billion in 2006 to $2.6 billion by 2015 (CAGR 200615 -6.0%). This will be primarily due to the launch of numerous generic anxiety drugs from 2006 onwards, which will offset the revenue growth derived from existing drugs seeking additional anxiety indications, and the launch of several novel anxiety drugs.

Scope
Detailed pipeline analysis for key products in development for GAD, SAD, OCD, PTSD, PMDD and panic disorder, plus drug sales forecasts to 2015
Overview of patient potential segmentation by indication and unmet needs in anxiety disorders across the US, Japan, France, Germany, Italy, Spain & UK
Benchmarking of key clinical and company attractiveness of late-phase pipeline products
Detailed clinical trial information and opinions from key thought leaders
Highlights
To maximize drug revenues as a final step before generic incursion, a number of existing market players are seeking approvals in additional anxiety indications. However, sales of $1.6 billion in 2006 will decline over the long-term to $1.2 billion in 2015.

Manufacturers with existing branded CNS drugs already approved for indications other than anxiety, are also seeking secondary indications in the anxiety market. Datamonitor forecasts that these drugs will enter the anxiety market from 2007 onwards, and will reach peak anxiety specific revenues of $413m in 2013.

Several novel anxiety drugs will be launched over the forecast period from 2006 onwards, including Predix's PRX-00023 (oral non-azapirone 5-HT1A agonist) in Phase III for GAD, and Schering AG/Berlex's YAZ (low dose drospirenone/ethinyl estradiol) and Wyeth's Librel (low dose levonorgestrel/ethinyl estradiol), both in development for PMDD.

Reasons to Purchase
Understand unmet needs in the anxiety market based on key opinion leader comments regarding both currently marketed and pipeline products
Benchmark key late-stage anxiety compounds against current market leaders
Assess the global sales forecasts of late-stage pipeline drugs for anxiety and examine their clinical and commercial potential

Introduction
The global anxiety disorders market is set to decline from $4.5 billion in 2006 to $2.6 billion by 2015 (CAGR 200615 -6.0%). This will be primarily due to the launch of numerous generic anxiety drugs from 2006 onwards, which will offset the revenue growth derived from existing drugs seeking additional anxiety indications, and the launch of several novel anxiety drugs.

Scope
Detailed pipeline analysis for key products in development for GAD, SAD, OCD, PTSD, PMDD and panic disorder, plus drug sales forecasts to 2015
Overview of patient potential segmentation by indication and unmet needs in anxiety disorders across the US, Japan, France, Germany, Italy, Spain & UK
Benchmarking of key clinical and company attractiveness of late-phase pipeline products
Detailed clinical trial information and opinions from key thought leaders
Highlights
To maximize drug revenues as a final step before generic incursion, a number of existing market players are seeking approvals in additional anxiety indications. However, sales of $1.6 billion in 2006 will decline over the long-term to $1.2 billion in 2015.

Manufacturers with existing branded CNS drugs already approved for indications other than anxiety, are also seeking secondary indications in the anxiety market. Datamonitor forecasts that these drugs will enter the anxiety market from 2007 onwards, and will reach peak anxiety specific revenues of $413m in 2013.

Several novel anxiety drugs will be launched over the forecast period from 2006 onwards, including Predix's PRX-00023 (oral non-azapirone 5-HT1A agonist) in Phase III for GAD, and Schering AG/Berlex's YAZ (low dose drospirenone/ethinyl estradiol) and Wyeth's Librel (low dose levonorgestrel/ethinyl estradiol), both in development for PMDD.

Reasons to Purchase
Understand unmet needs in the anxiety market based on key opinion leader comments regarding both currently marketed and pipeline products
Benchmark key late-stage anxiety compounds against current market leaders
Assess the global sales forecasts of late-stage pipeline drugs for anxiety and examine their clinical and commercial potential